MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Tenax Therapeutics Operating Expenses 2011-2026 | TENX
Annual Operating Expenses Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.4 M | 19.5 M | 8.23 M | 11.1 M | 32.7 M | 9.87 M | 8.56 M | 6.89 M | 9.21 M | 19.4 M | 13.8 M | 16.8 M | 6.13 M | 8.55 M | 10.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 56.4 M | 6.13 M | 15.8 M |
Quarterly Operating Expenses Tenax Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.8 M | 11.8 M | 11.3 M | - | 4.62 M | 3.67 M | 3.91 M | - | 2.12 M | 1.24 M | 1.54 M | - | 2.92 M | 2.86 M | 2.72 M | - | 3.8 M | 1.96 M | 23.7 M | - | 2.23 M | 2.14 M | -2.67 M | - | -2.26 M | -1.82 M | -1.66 M | - | -1.55 M | -1.89 M | -1.22 M | - | -1.31 M | -3.01 M | -3.5 M | - | -4.5 M | -4.67 M | 5.71 M | 3.13 M | 3.1 M | 3.75 M | 3.11 M | 2.47 M | 4.14 M | 4.14 M | 2.42 M | 1.81 M | 2.17 M | 2.17 M | 1.76 M | 2.02 M | 1.2 M | 1.2 M | 1.95 M | 2.78 M | 2.15 M | 2.15 M | 2.45 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.7 M | -4.67 M | 2.5 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.85 | 3.22 % | $ 9.26 B |  Australia |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.13 B | $ 330.55 | -0.85 % | $ 43.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Aligos Therapeutics
ALGS
|
90.2 M | $ 7.51 | 1.21 % | $ 74.2 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.68 | - | $ 1.01 B | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 99.49 | 0.02 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Burford Capital Limited
BUR
|
106 M | $ 4.79 | 1.06 % | $ 771 M | Britain |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Cabaletta Bio
CABA
|
172 M | $ 3.46 | 1.62 % | $ 348 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.17 | -2.16 % | $ 5.22 M | Israel |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
64.6 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
173 M | $ 1.5 | -3.23 % | $ 386 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.24 | -0.12 % | $ 453 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 24.54 | -0.18 % | $ 3.12 B | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.48 | -1.01 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 33.97 | 0.3 % | $ 2.26 B | USA |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
16 M | $ 2.67 | -2.91 % | $ 1.18 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |